Percentage of shares held in treasury

Summary by AI BETAClose X

Convatec Group Plc has announced that its treasury shareholding exceeded 5% of the company's voting rights on August 6, 2026, and as of August 17, 2026, it held 102,469,942 ordinary shares in treasury, representing 5.26% of the total voting rights. This increase is a result of share purchases made under the company's buyback programme of up to $200 million, which was initially announced on August 4, 2026.

Disclaimer*

Convatec Group PLC
21 August 2026
 

21 August 2026

Convatec Group Plc
 ("Convatec" or the "Company")

Percentage of shares held in treasury

London, UK, 21 August 2026: The Company announces that as a result of its purchases of ordinary shares of 10 pence each (ordinary shares) through Morgan Stanley & Co. International plc (Morgan Stanley), as part of the share buyback programme of up to $200m announced on 4 August 2026 (the Programme), the percentage of its share capital held in treasury exceeded 5% of the Company's voting rights on 6 August 2026.

 

With the additional share purchases announced by the Company on 17 August 2026, the Company held 102,469,942 of its ordinary shares in treasury as of 17 August, representing 5.26% of the total voting rights in the Company.

 

This announcement is made pursuant to Rule 5.5.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules and was intended to be made within four trading days of 6 August 2026, when the Company first crossed the 5% threshold referred to above.

 

Contacts
 Company Secretariat: CoSec@convatec.com 
Media: mediarelations@convatec.com
 Analysts & investors: ir@convatec.com         

 

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Convatec Group (CTEC)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today